HANSOH PHARMA(HK:03692) Xin Lang Cai Jing·2026-01-13 03:54Core Viewpoint - Hansoh Pharmaceutical (03692) has received approval from the National Medical Products Administration (NMPA) for its innovative drug Amelot (Ametinib Mesylate Tablets) to be used in combination with pemetrexed and platinum-based chemotherapy for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations. This marks the fifth indication approved for Amelot [1][1][1]. Group 1 - Hansoh Pharmaceutical's stock rose over 4% and was trading at HKD 42.12 with a transaction volume of HKD 97.62 million at the time of reporting [1][1][1]. - The newly approved indication for Amelot targets adult patients with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations [1][1][1]. Group 2 - Recent research published in the prestigious oncology journal Lancet Oncology indicates that Amelot significantly improves disease-free survival (DFS) in patients with completely resected stage II-III B EGFR-mutant NSCLC, demonstrating good safety [1][1][1].